Research Insights

Exclusive Interview with the Researcher: Michael DiStefano, PhD, MBE, on Compounded GLP-1s


"Our most surprising finding was just how many different compounders are participating in this market, some of which do not appear to have the appropriate licensing…"

Michael J. DiStefano, PhD, MBE

University of Colorado Anschutz

The percentage of US adults currently taking GLP-1 medications for weight loss rose to 11% in 2026, up significantly from 3% in 2024. Of those using GLP-1 medications, 19% reported using a compounded or custom-mixed version of the medicine (68% reported using brand-named drugs, and 12% were unsure). The availability of compounded GLP-1s — which have not undergone the Food and Drug Administration (FDA) approval process — expanded rapidly during GLP-1 shortages. Despite the shortages ending, the market for compounded alternatives remains robust, and the FDA has increased oversight of compounded GLP-1s due to concerns about dosing errors and product quality.

A recent JAMA publication by Michael J. DiStefano, PhD, MBE, and team examined the post-shortage GLP-1 receptor agonist market in two states with potentially high demand, Oklahoma and West Virginia. Learn more in this exclusive interview with Dr. Michael DiStefano:

 

Q: What surprised you the most about your findings on the continued demand for compounded GLP-1 medications?

A: What we found supported what many have expected, which is that post-shortage, these suppliers would shift more toward producing GLP-1s combined with other ingredients to differentiate them from the branded products. Our most surprising finding was just how many different compounders are participating in this market, some of which do not appear to have the appropriate licensing or have been the recipient of disciplinary actions from the FDA or state boards of pharmacies. I think it is very challenging for even very motivated regulators to adequately oversee this market right now.

 

Q: What are the patient safety concerns and drug efficacy concerns surrounding compounded GLP-1s?

A: Certainly there are safety concerns for patients who are receiving their compounded GLP-1s from facilities without the appropriate sterile compound licensing. It is also possible that combining GLP-1s with other ingredients like B vitamins or levocarnitine impacts the safety and effectiveness of these drugs.

 

Q: What implications might these findings have for patient medication adherence, utilization, and overall health care costs?

A: The compounded market has created access for many people who would not otherwise have been able to afford the branded products and who genuinely stand to benefit from losing weight. Anecdotally, I’ve also heard from people who have been able to stop drinking and using other drugs since starting on a compounded GLP-1. Of course, and leaving aside the legal issues, this expanded access is only a good thing for these people if the compounded products are produced safely and effectively. I also don’t think it is a stretch to say that the existence of the compounded market has put pressure on Novo and Lilly to find ways to bring down the cost of their branded products.

 

Q: Given that this study examined compounding pharmacies in Oklahoma and West Virginia, which are both more than 30% rural, how are you thinking about the relevance of your takeaways to compounding pharmacies in more urban states versus more rural ones?

A: Of course, our study findings should not be seen as generalizable across the US. I think one difference between urban and rural areas could be that people in rural areas might turn more often to telehealth options (which probably work with the larger 503B compounders that are overseen by the FDA), while those in urban areas have easier access to in-person med spas (which may be more likely to work with the smaller 503A pharmacies under state board of pharmacy oversight). One thing I would like to see data on is how people’s experiences differ between telehealth and in-person options.

 

Q: What should policymakers and health care leaders take away from this analysis?

A: I think the compounded market is only going to grow as peptides beyond GLP-1s become more popular and as the current administration potentially eases restrictions on compounders who want to produce unapproved peptides like BPC-157. It worries me a little that dedicated regulators like the FDA and state boards of pharmacy might already be struggling to stay on top of this market. What sorts of regulatory innovation are needed to address this brave new world of drug compounding?

 

Read NIHCM’s 2026 Trade Journalism Award winner’s story examining a rapidly growing compounding pharmacy and identifying questionable practices, including poor-quality ingredients and suppressed employee concerns.

 


More Related Content